Schlich Ltd +44(0) 1903 717001 info@schlich.co.uk
  • EN
  • 中文
  • 한국어
  • 日本語
  • Client Portal
Schlich Ltd
  • Our Firm
  • IP Services
    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy
  • Patent Specialities
    • Life Sciences & Biotech
    • Chemical & Pharmaceutical
    • Mechanical, Engineering and Physics
    • Software, Electronics and Communications
  • Insights
  • Inventors’ Zone
  • Contact
Select Page
The Federal Circuit clarifies conflicts arising between Patent Term Adjustment and Obviousness-type Double Patenting

The Federal Circuit clarifies conflicts arising between Patent Term Adjustment and Obviousness-type Double Patenting

by David Eyre | Sep 16, 2024 | US & International

Background  For valuable inventions it is relatively typical for a US patent to be expanded into a family of patent rights. Naturally, the value of patents is further enhanced by extra patent term.  Patents with expiry dates beyond the normal 20 year period can be...
What Satisfies the Palate of the EPO’s Boards of Appeal? Fish Oil and Fruit Juice, Apparently…

What Satisfies the Palate of the EPO’s Boards of Appeal? Fish Oil and Fruit Juice, Apparently…

by Sean Hutchinson | Aug 30, 2024 | EPO

Background European patent no. EP 2 991 507 B1 was granted with claims directed to a mixture containing fish oil and fruit juice for use in the treatment of cancer. At opposition, the patent was found to lack novelty and the amendments proposed by the patent...
Boards of Appeal Introduce New Broad Interpretation of “Substance or Composition” in the Context of Second Medical Use Claims

Boards of Appeal Introduce New Broad Interpretation of “Substance or Composition” in the Context of Second Medical Use Claims

by Chloe Sullivan | Aug 29, 2024 | EPO, Uncategorised

Background Due to methods of treatment of the human or animal body being excluded from patentability in Europe, applicants are required to claim substances or compositions for use in a method of treatment instead. Thus, there is a need for the term “substances or...
Therapeutic Effect – a Higher Bar for Novelty than for Sufficiency at the EPO

Therapeutic Effect – a Higher Bar for Novelty than for Sufficiency at the EPO

by David Eyre | Jul 8, 2024 | EPO

These provisions for “second medical use” also rely on the claims for use in a method of treatment being interpreted to include the physiological or technical effect of the treatment as being a functional feature of the claim.   However, the interpretation...
New Hope for Antibody Claims in the US

New Hope for Antibody Claims in the US

by Juliette Boynton | Jul 2, 2024 | US & International

However, in a significant development we now report, means-plus-function language for a claim to an antibody complied with both of the USPTO requirements for written description and for the claim not to be indefinite. Where functional language alone is used in US...
« Older Entries
Next Entries »

Search

Recent Posts

  • Squeezed Out! AstraZeneca overturns Wyeth’s $107.5M Infringement Award
  • UPC Court of Appeal Confirms Lock-in Danger
  • When “Monotherapy” Means Monotherapy: A Cautionary Tale on Claim Interpretation and Added Matter at the EPO
  • Has the EPO TBA Demolished the Essentiality Test?
  • A Clear Way Forward for Description Amendments: Decision Issued in G 1/25

Recent Comments

    CIPA
    IPReg
    CITMA
    • Instagram

    Services

    • Patents
    • EPO Oppositions & Appeals
    • UKIPO Proceedings
    • UPC Proceedings
    • Trade Marks
    • Designs
    • IP Strategy

    About

    • Our Firm
    • Careers
    • Our People
    • Policies

    Contact

    • Contact
    • Inventors Zone
    © 2026 Schlich, All rights reserved | Built by Molokini
    European Patent and Trade Mark Attorneys. Schlich Ltd is a UK limited company, registration no. 05238489, address: 9 St Catherine's Road, Littlehampton, West Sussex, BN17 5HS.